BRPI0413740A - composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo - Google Patents

composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo

Info

Publication number
BRPI0413740A
BRPI0413740A BRPI0413740-0A BRPI0413740A BRPI0413740A BR PI0413740 A BRPI0413740 A BR PI0413740A BR PI0413740 A BRPI0413740 A BR PI0413740A BR PI0413740 A BRPI0413740 A BR PI0413740A
Authority
BR
Brazil
Prior art keywords
oxide
pharmaceutically acceptable
acceptable salt
compound
composition
Prior art date
Application number
BRPI0413740-0A
Other languages
English (en)
Inventor
Arlindo L Castelhano
Andrew Philip Crew
Han-Qing Dong
Radoslaw Laufer
An-Hu Li
Li Qiu
Colin Peter Sambrook Smith
Tao Zhang
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of BRPI0413740A publication Critical patent/BRPI0413740A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTO OU UM SEU N-óXIDO OU SEU SAL FARMACEUTICAMENTE ACEITáVEL, COMPOSIçãO, E, MéTODO DE TRATAMENTO DE DISTúRBIO HIPERPROLIFERATIVO". Compostos representados pela fórmula (I): ou um seu N-óxido ou seu sal farmaceuticamente aceitável, são úteis no tratamento de câncer.
BRPI0413740-0A 2003-08-21 2004-08-16 composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo BRPI0413740A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49677603P 2003-08-21 2003-08-21
PCT/US2004/026483 WO2005021544A2 (en) 2003-08-21 2004-08-16 N3-substituted imidazopyridine-derivatives as c-kit inhibitors

Publications (1)

Publication Number Publication Date
BRPI0413740A true BRPI0413740A (pt) 2006-10-24

Family

ID=34272515

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413740-0A BRPI0413740A (pt) 2003-08-21 2004-08-16 composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo

Country Status (20)

Country Link
EP (1) EP1658289B1 (pt)
JP (1) JP2007502822A (pt)
KR (1) KR20060119871A (pt)
CN (1) CN1839132A (pt)
AP (1) AP2006003552A0 (pt)
AR (1) AR045388A1 (pt)
AT (1) ATE425977T1 (pt)
AU (1) AU2004268950A1 (pt)
BR (1) BRPI0413740A (pt)
CA (1) CA2536174A1 (pt)
DE (1) DE602004020073D1 (pt)
IL (1) IL173615A0 (pt)
IS (1) IS8318A (pt)
MX (1) MXPA06002019A (pt)
MY (1) MY138737A (pt)
NO (1) NO20060670L (pt)
RU (1) RU2006108799A (pt)
SG (1) SG131944A1 (pt)
TW (1) TW200519111A (pt)
WO (1) WO2005021544A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006704A (es) 2006-12-22 2009-06-30 Astex Therapeutics Ltd Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
GB0625827D0 (en) * 2006-12-22 2007-02-07 Astex Therapeutics Ltd New compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
CN105418450A (zh) 2008-05-05 2016-03-23 赛诺菲-安万特 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
MY153606A (en) * 2008-08-05 2015-02-27 Daiichi Sankyo Co Ltd Imidazopyridin-2-one derivatives
US20110190336A1 (en) * 2008-10-16 2011-08-04 Cara Therapeutics, Inc. Azabenzimidazolones
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
BR112012016398B1 (pt) * 2009-12-30 2021-12-21 Arqule, Inc Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
KR20190015600A (ko) * 2011-06-24 2019-02-13 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
ES2664985T3 (es) 2012-12-21 2018-04-24 Plexxikon Inc. Compuestos y métodos para modulación de quinasa, e indicaciones de los mismos
US9464083B2 (en) * 2014-03-24 2016-10-11 Arqule Inc. Process of preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-B]pyridin-2-yl)pyridin-2-amine
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
EP3594205A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-aryl derivatives for treating a rna virus infection
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202428265A (zh) * 2022-11-30 2024-07-16 日商亞力維克希斯股份有限公司 Kit抑制劑、化合物、醫藥組合物、及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW251284B (pt) * 1992-11-02 1995-07-11 Pfizer
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
EP1255750A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
JP2007502822A (ja) 2007-02-15
EP1658289B1 (en) 2009-03-18
KR20060119871A (ko) 2006-11-24
MY138737A (en) 2009-07-31
ATE425977T1 (de) 2009-04-15
WO2005021544A3 (en) 2005-06-16
RU2006108799A (ru) 2006-07-27
SG131944A1 (en) 2007-05-28
TW200519111A (en) 2005-06-16
EP1658289A2 (en) 2006-05-24
AU2004268950A1 (en) 2005-03-10
IS8318A (is) 2006-02-21
NO20060670L (no) 2006-05-12
CA2536174A1 (en) 2005-03-10
MXPA06002019A (es) 2006-05-31
IL173615A0 (en) 2006-07-05
WO2005021544A2 (en) 2005-03-10
AP2006003552A0 (en) 2006-04-30
AR045388A1 (es) 2005-10-26
DE602004020073D1 (de) 2009-04-30
CN1839132A (zh) 2006-09-27

Similar Documents

Publication Publication Date Title
BRPI0413746A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
BRPI0413785A (pt) composto, composição, e, método de tratamento de distúrbio hiperproliferativo
BRPI0413740A (pt) composto ou um seu n-óxido ou seu sal farmaceuticamente aceitável, composição, e, método de tratamento de distúrbio hiperproliferativo
BR0214485A (pt) 3-cianoquinolinas como inibidores de egf-r e her2 quinases
HK1085675A1 (en) Anticancer compounds
BRPI0411365A (pt) derivados de aminopiridina
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
MXPA04002537A (es) Alquinos como inhibidores de metaloproteinasa de matriz.
BRPI0518794A2 (pt) composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial
BR0313732A (pt) Compostos de pirimido tendo atividade antiproliferativa
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ATE452896T1 (de) C3-cyanoepothilonderivate
DK1056704T3 (da) Antitumormidler
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
MXPA04006041A (es) Antivirales de piridoquinoxalina.
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
IL165259A0 (en) Compounds useful in the treatment of anthraxa and inhibiting lethal factor
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
NO20055998L (no) Diarylmetylidenpiperidinderivater, preparater derav og anvendelse derav
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
SG146685A1 (en) Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them
BRPI0409768A (pt) composto, uso de composto, composição farmacêutica, método para tratar e/ou prevenir cáncer, e, processo para preparar o composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.